In a notice to the London Stock Exchange, Pfizer has announced an increase in its proposed cash and share offer for AstraZeneca Plc to £50 per share valuing the company at £64 billion. In a separate statement, AstraZeneca said its board will meet to discuss the indicative proposal.
